Biopartnerships - Pharmaceutical Executive

ADVERTISEMENT

Biopartnerships

Value Today for Drugs Tomorrow

October 1, 2005

Fda-approved drugs represent a company's prospects today. Drugs in the pipeline embody the company's future. But when it comes to analyzing the value of a pharma company, the pipeline is often overlooked.

An 11-Step Program to Navigating Partnerships

October 1, 2005

In some cases simply contemplating a potential partnership will lead a company to reconsider some of its basic business strategies. That's fine, as long as everyone is clear on one thing: The important goal isn't to make a partnership. The important goal is to advance the business.

It's All Academic: Biotechs Looking to Universities

October 1, 2005

Academic institutions look for a strong committment from the company's senior management, favorable deal terms, market depth in a specific therapeutic area, and alignment with the partner's core strategy.

Successful Alliances: Novartis and Idenix Share the Secrets of Success

October 1, 2005

When it comes to infectious diseases, biotech start-up Idenix is on a mission: to provide patients with treatments that are more effective, more tolerable, and safer than current standards of care. Though small, the Cambridge, Massachusetts-based company is well poised to become a leader in the global antiretroviral market: It has experienced top management, a strong background in medicinal chemistry and drug discovery, and a pipeline of novel treatments for hepatitis B and C and HIV. Until a couple years ago, all Idenix lacked was a financial backer to help pay the way.

Risks and Rewards: How to Protect the Hand You're Dealt

October 1, 2005

Poker has become one on the most popular attractions on television and the Internet, right up there with online auctions. And if the two were ever combined—so that players could auction off their hand early in a game, with several rounds of cards remaining to be dealt—bidders might seek advice from folks in pharmaceutical business development. Because that's what we do. When we buy or sell the rights to a compound in development, we are putting a price on a gamble.

Considering Intangibles

October 1, 2005

In order to make the deal work, Argos had to spend a lot of time building the relationship. Taking the time to get to know and trust one another was a key component of Kirin's due diligence process.

Introduction: Learning Lessons and Looking Ahead

October 1, 2005

There's more than one way to slice and dice a deal to understand how value is distributed. In doing so, companies may be better able to construct biopartnerships that not only capitalize on the promise offered by a compound today, but minimize them against losses if a drug doesn't succeed through the pipeline.

Seven Principles for Fostering Partnerships

October 1, 2005

The backbone of the business development process is a series of decision gates with agreed upon decision criteria, and clear expectations for the appropriate levels of research and analysis for each stage in the process.

Back to the Pharma Future

October 1, 2004

Recognize that the drug drought is the "disease" underlying many of pharma's troubling symptoms, and the cure becomes apparent.

ADVERTISEMENT

Click here